highly significantP <0.0001
After 1 year of follow‐up, the overall prevalence of symptoms decreased to 49% among women and 33% among men, but the sex‐specific difference remained highly significant ( P <0.0001).
After 1 year of follow‐up, the overall prevalence of symptoms decreased to 49% among women and 33% among men, but the sex‐specific difference remained highly significant ( P <0.0001).